Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Equity (2020 - 2025)

Barinthus Biotherapeutics' Return on Equity history spans 6 years, with the latest figure at 0.84% for Q4 2025.

  • For Q4 2025, Return on Equity fell 41.0% year-over-year to 0.84%; the TTM value through Dec 2025 reached 0.84%, down 41.0%, while the annual FY2025 figure was 0.65%, 26.0% down from the prior year.
  • Return on Equity reached 0.84% in Q4 2025 per BRNS's latest filing, down from 0.81% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.62% in Q1 2021 to a low of 0.84% in Q4 2025.
  • Average Return on Equity over 5 years is 0.29%, with a median of 0.37% recorded in 2024.
  • Peak YoY movement for Return on Equity: plummeted -91bps in 2021, then skyrocketed 39bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.19% in 2021, then skyrocketed by 111bps to 0.02% in 2022, then crashed by -1858bps to 0.38% in 2023, then fell by -10bps to 0.42% in 2024, then tumbled by -98bps to 0.84% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Return on Equity are 0.84% (Q4 2025), 0.81% (Q3 2025), and 0.64% (Q2 2025).